Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool August 15, 2007 Brian Orelli	Little Fish in a Big Pond Small generic-drug maker Caraco Pharmaceutical Laboratories holds its own in a sector where big is almost always better. It does so by having made an intelligent partnership deal and by expanding its product line.
InternetNews January 24, 2008 Andy Patrizio	Sun Tops Estimates in Second Quarter Total sales for Sun Microsystems came in slightly higher than expected and profits almost doubled from the year-ago quarter.
InternetNews August 7, 2007 Andy Patrizio	Sun Plans More Job Cuts Despite a successful quarter that surpassed analysts expectations, Sun Microsystems is poised for more job cuts.
BusinessWeek April 18, 2005 Manjeet Kripalani	India: Bigger Pharma Tougher patent protection laws are spurring rapid growth in new drug research across India.
InternetNews July 22, 2010	Oracle Looks to Calm Sun Customer Concerns A Garter report found that Sun customers aren't happy with the flow of information from the company's new owner. Now Oracle is moving to calm frustrated Sun users.
The Motley Fool June 29, 2009 Brian Orelli	Your Company Has Been Raided. What Now? Lately, investors have had to worry about pharmaceutical companies keeping their drugs on the market.
The Motley Fool August 6, 2008 Rich Smith	Twilight for Sun Hydraulics? Let's take a look at Sun Hydraulics, a small-cap manufacturer of screw-in hydraulic cartridge valves and manifolds, and see how their valuation looks.
The Motley Fool July 14, 2005 Stephen D. Simpson	These Swiss Don't Miss Aside from a hiccup in margins, Novartis' drug business continues to shine. This pharma is a solid middle-of-the-road play with reasonable valuation, a solid pipeline, and a not-so-secret weapon in its Sandoz generics business.
InternetNews January 27, 2009 Andy Patrizio	Sun Just Misses Profit on Modest Sales Slide Sun Microsystems has been declared dead plenty of times. But its most recent quarter shows the company is very much alive - with some of its products even proving hits.
BusinessWeek December 8, 2003 Gene G. Marcial	More Dentists Are Drilling With Biolase Biolase makes laser dental drills quieter and less painful. The stock was knocked down because of an accounting restatement, but some pros think it is a good buy.
The Motley Fool May 2, 2008 Anders Bylund	Sun's Cloudy Vision Sun Microsystems publishes a train wreck of a quarterly report.
InternetNews September 2, 2009	EU May Delay Oracle-Sun Nuptials Sun just can't get a break as European investigators might stall its proposed merger with Oracle.
InternetNews March 18, 2009 Andy Patrizio	Would a Sun-IBM Marriage Work? Overlapping products and vastly different cultures will present challenges in a merger between IBM and Sun. But if they make it work, the results could be great for both sides.
The Motley Fool March 26, 2010 Anders Bylund	Oracle Kicks Sun Into Shape There's more kicking to be done, but Larry Ellison's changes at Sun make a lot of sense.
InternetNews April 18, 2005 Paul Shread	Earnings Season Swings Into High Gear Yahoo, Intel, eBay and Google are among the names reporting this week... TI beats estimates... Adobe falls on plans to acquire Macromedia... etc.
InternetNews December 9, 2008 Paul Shread	Sun's Financial Failings Greatly Exaggerated If you're expecting Sun Microsystems to be rescued by a white knight, you'll be disappointed: The company doesn't need to be saved.
The Motley Fool January 3, 2008 Brian Orelli	8 Generic-Drug Makers for 2008 Generic-drug makers can predict the growth of their industry, because it's written right in the patent-expirations column of the FDA's orange book. Here's a brief look at eight generic-drug makers worth closer scrutiny.
InternetNews October 20, 2008 Andy Patrizio	Sun Preliminary Quarterly Figures Show a Drop While not final, they tend to be a fairly accurate indicator of where things will fall, and in this case, they are falling short.
BusinessWeek December 22, 2003 Gene G. Marcial	With US Dataworks, Checks Clear Pronto Check 21, the new law allowing electronic check clearing, has been a boon to tiny American Stock Exchange-listed US Dataworks, whose stock is up from 1.50 in June to 3.24 on Dec. 10. US Dataworks makes software that lets banks transmit checks electronically.
InternetNews December 15, 2009	HP Gets Aid in Wooing Sun's Server Customers HP is enlisting some aid in making its play for Sun customers even strong.
InternetNews April 6, 2009 Andy Patrizio	The Sun Doesn't Set Just Yet After reports say it spurned its suitor, IBM, what's ahead for Sun?
The Motley Fool July 27, 2009 Brian Orelli	Mylan Ruins It for Everyone If customers begin to mistrust generic drugs from Mylan or whoever -- fearing that the companies are putting profits above safety -- all generic-drug companies will be hurt.
InternetNews November 17, 2008 Andy Patrizio	What's Next for Sun? Can Sun cut its way to profitability and prominence, or is it just looking for a graceful exit - and friendly buyer - at this point.
BusinessWeek November 3, 2003	The Heavy Trading In Strategic Diagnostics Strategic Diagnostics, which makes immunoassay tests to detect toxicity in foodstuffs, has risen since September from 3.90 to 4.87 -- on heavy volume. Herbert Lotman, who owns Keystone Foods and sits on Strategic's board, has been buying shares, and it is rumored that he may make a run for Strategic.
The Motley Fool September 2, 2009 Eric Jhonsa	Why Oracle's Getting More Than It Bargained For Sun's earnings show just how weak its hardware business is.
BusinessWeek October 10, 2005 Manjeet Kripalani	India: A Quiet Shopping Spree So far, foreign companies being bought by Indian players are small - but that's likely to change
The Motley Fool January 28, 2009 Anders Bylund	Sun Is Overdone Pick a business or split in two. This indecision won't cut it.
The Motley Fool February 15, 2005 Stephen D. Simpson	Teva: Scourge of the Drug World? The world's largest generics maker continues to post strong growth by bedeviling Big Pharma.
InternetNews November 9, 2009	Sun Hangs In There Despite Tough Q1 It's rough times for the company but a recent SEC filing shows it's not just shriveling up.
InternetNews August 8, 2005 Colin C. Haley	ETrade Jumps On Acquisition Investors like ETrade 's $700M purchase of Harrisdirect... Traders were eyeing Cisco and Nokia... Other network equipment companies fared well... etc.
The Motley Fool February 22, 2005 Brian Gorman	Novartis Embraces Generics The company is taking a different path from its branded pharmaceutical peers. The company's strategy may make its stock worth a closer look.
InternetNews June 23, 2009 Andy Patrizio	Sun Expands HPC Hardware and Software Rumors be damned, Sun continues to beef up its high performance computing product line.
The Motley Fool April 6, 2009 Anders Bylund	IBM's Sun Deal Flames Out But this star may rise again.
Managed Care August 2004	MCOs, Drug Manufacturers Have Lots of PR Work to Do Managed care companies, and pharmaceuticals especially, receive disheartening numbers in a consumer satisfaction poll.
InternetNews September 14, 2009	Some Customers Are Sticking With Sun As HP and IBM aggressively pitch Sun customers, many are hanging in there. Oracle plans to debut a new Sun/Oracle database system this week.
InternetNews November 10, 2008 Judy Mottl	Sun Embarks on New Storage 'Road' Sun pushes out first open storage appliance on Open Solaris platform, offering an inexpensive take on network storage.
InternetNews April 15, 2005 Chris Nerney	Wire-to-Wire Rout Sinks Stocks Overall market closes down... IBM earnings below estimates... Sun's revenue is down... etc.
The Motley Fool August 18, 2009	Today's 5-Star Movers A list of today's top-moving stocks from the Motley Fool five-star stock list.
InternetNews August 10, 2005 Colin C. Haley	Oil Tamps Techs Concerns over oil prices loomed, as the Nasdaq, S&P, and Dow all lost ground... Yahoo edged up as rumblings continued that the portal giant was close to purchasing a Chinese e-Commerce firm... Cisco posted solid, but unspectacular, results and fell... etc.
The Motley Fool October 29, 2009	Today's 5-Star Movers Today's top-moving stocks from the Motley Fool five-star stock list: Kaydon Corp... Akamai...
The Motley Fool January 25, 2010 Anders Bylund	Cue the Titanic Culture Clash! An internal memo gives us a glimpse into the minds of Sun's leaders -- and it doesn't look good.
InternetNews December 30, 2004 Erin Joyce	Sluggish Session on Wall Street Jobless claims fell... LightPath CEO will leave... Computer Sciences gains contract... etc.
The Motley Fool February 22, 2005 Rich Duprey	Merger Mania Besets Japanese Pharmaceuticals A new law spurs megamergers in Japan's pharmaceutical industry. Stocks of companies seen as particularly interesting, including Eisai, Mitsubishi Pharma, and Shionogi, all jumped more than 2%.
BusinessWeek January 10, 2005 Mara Der Hovanesian	Barr: A No-Name Star More than $30 billion in patents will elapse by the end of 2007, which spells new potential for generics such as Barr Pharmaceuticals. With Barr's solid pipeline, the stock, at $46, is a bargain.
BusinessWeek November 3, 2003 Diane Brady	Biotech: Teva's Next Triumph? The Israeli maker of generics wants a piece of the fast-growing bio-drug market.
The Motley Fool September 11, 2009	Today's 5-Star Movers A list of today's top-moving stocks from the Motley Fool five-star stock list.
The Motley Fool April 21, 2005 Stephen D. Simpson	Novartis' Triple Threat The Swiss drug giant boasts strong franchises in generics, cardiology, and oncology. It's hard not to think of Novartis as one of the highest-quality options in the pharmaceutical investing space.
The Motley Fool August 1, 2005 Stephen D. Simpson	Teva: Built to Last? Israeli generics giant Teva Pharmaceuticals is a high-quality company trading at a level that should still provide patient investors with solid long-term performance.
The Motley Fool February 17, 2005 Stephen D. Simpson	Caremark Hits the Mark Again With expectations of higher than 25% growth in 2005, the pharmacy benefits manager looks like it will continue to take care of its investors.
National Real Estate Investor February 11, 2003 Parke Chapman	EOP reports fourth-quarter results A weak office and apartment market is having a pronounced effect on the nation's bellwether REITs.